Mario A Eisenberger

Mario A Eisenberger

UNVERIFIED PROFILE

Are you Mario A Eisenberger?   Register this Author

Register author
Mario A Eisenberger

Mario A Eisenberger

Publications by authors named "Mario A Eisenberger"

Are you Mario A Eisenberger?   Register this Author

100Publications

3124Reads

39Profile Views

Progress in the Systemic Management of Advanced Prostate Cancer: The Hormone-Sensitive Paradigm.

J Clin Oncol 2019 Nov 4;37(32):2957-2960. Epub 2019 Sep 4.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.01863DOI Listing
November 2019

Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype.

Prostate 2019 Sep 7;79(13):1572-1579. Epub 2019 Aug 7.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23881DOI Listing
September 2019

Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.

Eur Urol 2019 Aug 4;76(2):170-176. Epub 2018 Oct 4.

Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA; Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838183072
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2018.09.040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447475PMC
August 2019

Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.

Eur Urol 2019 Jun 5. Epub 2019 Jun 5.

Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA; Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2019.05.032DOI Listing
June 2019

There Is Now Compelling Evidence to Further Evaluate Lower Doses of Abiraterone Acetate in Men With Metastatic Prostate Cancer: It Should Be Safer, May Be as Effective and Less Expensive.

J Clin Oncol 2018 10 6;36(30):3059-3060. Epub 2018 Sep 6.

Pedro Isaacsson Velho and Mario A. Eisenberger, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.79.3166
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.79.3166DOI Listing
October 2018

Reply to M. Horiguchi et al.

J Clin Oncol 2018 03 26;36(8):826-827. Epub 2018 Jan 26.

Mario A. Eisenberger, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wenping Zhang, Sanofi, Bridgewater, NJ; Zhenming Shun, Sanofi, Cambridge, MA; and Johann de Bono, Royal Marsden National Health Service Foundation Trust/The Institute of Cancer Research, Sutton, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.3748DOI Listing
March 2018

Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.

J Clin Oncol 2017 Oct 20;35(28):3181-3188. Epub 2017 Jun 20.

Emmanuel S. Antonarakis and Mario A. Eisenberger, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Scott T. Tagawa, Giuseppe Galletti, Daniel Worroll, Karla Ballman, Ada Gjyrezi, Shinsuke Tasaki, Luigi Portella, Yang Bai, Brian J. Kirby, David M. Nanus, and Paraskevi Giannakakou, Weill Cornell Medicine/Meyer Cancer Center; Che-Kai Tsao, Mount Sinai Medical Center, New York; Timothy B. Lannin, Shalu Suri, Conor N. Gruber, Erica D. Pratt, and Brian J. Kirby, Cornell University, Ithaca, NY; Marie Vanhuyse, Medical Oncology, Montréal General Hospital; Fred Saad, University of Montreal Hospital Center, Montreal; John Stewart, Atef Zaher, and Wei Zhou, Sanofi, Laval, Quebec, Canada; Guru Sonpavde, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; Scott North, University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada; Costantine Albany, Indiana University School of Medicine, Indianapolis, IN; and Ted Szatrowski, Sanofi, Bridgewater, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.4138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791829PMC
October 2017

Extreme Response to High-dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer.

Eur Urol 2017 03 29;71(3):499. Epub 2016 Sep 29.

Department of Oncology, Johns Hopkins Medicine, Baltimore, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2016.09.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808412PMC
March 2017

A Potential Predictive Role for Prostate-specific Antigen Changes at 4 Weeks?

Eur Urol 2016 11 5;70(5):732-733. Epub 2016 Apr 5.

Genitourinary Oncology Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University, Baltimore, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2016.03.032DOI Listing
November 2016

Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.

Prostate 2016 09 24;76(13):1218-26. Epub 2016 Jun 24.

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23209DOI Listing
September 2016

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.

J Clin Oncol 2016 05 7;34(14):1652-9. Epub 2016 Mar 7.

Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.65.7270
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.65.7270DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872320PMC
May 2016

A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer.

J Urol 2016 Apr 18;195(4 Pt 1):880-5. Epub 2015 Nov 18.

Department of Oncology, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Department of Urology, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2015.11.024DOI Listing
April 2016

Intermittent Androgen Deprivation in Prostate Cancer: Are We Ready to Quit?

J Clin Oncol 2016 Jan 30;34(3):211-4. Epub 2015 Nov 30.

Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.1019DOI Listing
January 2016

Advances in the Treatment of Metastatic Prostate Cancer.

Mayo Clin Proc 2015 Dec;90(12):1719-33

Genito-Urinary Oncology Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University, Baltimore, MD. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2015.10.010DOI Listing
December 2015

Sarcomatoid Carcinoma of the Prostate: Retrospective Review of a Case Series From the Johns Hopkins Hospital.

Urology 2015 Sep 28;86(3):539-43. Epub 2015 Jun 28.

Division of Medical Oncology, Sidney Kimmel Cancer Center, The Johns Hopkins University, Baltimore, MD. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2015.06.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569516PMC
September 2015

Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.

Mol Imaging Biol 2015 Aug;17(4):565-74

The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Cancer Research Bldg. 2, Room 492, 1550 Orleans St, Baltimore, MD, 21231, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11307-015-0850-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531836PMC
August 2015

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

N Engl J Med 2014 Sep 3;371(11):1028-38. Epub 2014 Sep 3.

From the Departments of Oncology (E.S.A., H.W., B.L., J.T.I., R.N., C.J.P., S.R.D., M.A.C., M.A.E.), Pathology (H.L.F., T.L.L., Q.Z., A.M.D.M.), and Urology (C.L., M.N., J.C.R., Yan Chen, W.B.I., J.L.), Johns Hopkins University School of Medicine, Baltimore; and Greehey Children's Cancer Research Institute (T.A.M., Yidong Chen) and the Department of Epidemiology and Biostatistics (Yidong Chen), University of Texas Health Science Center at San Antonio, San Antonio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1315815DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201502PMC
September 2014

Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.

Eur Urol 2014 Aug 11;66(2):330-6. Epub 2013 Aug 11.

Department of Medical Oncology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2013.08.007DOI Listing
August 2014

Determining the optimal treatment for metastatic castration-resistant prostate cancer: age should not be a factor.

Eur Urol 2014 May 16;65(5):884-6. Epub 2013 Oct 16.

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838130107
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2013.10.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090698PMC
May 2014

Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial.

J Geriatr Oncol 2014 Apr 2;5(2):119-26. Epub 2014 Jan 2.

Department of Medical Oncology, Princess Margaret Hospital, University Health Network and the University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2013.12.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352315PMC
April 2014

Small cell carcinoma of the prostate.

Nat Rev Urol 2014 Apr 18;11(4):213-9. Epub 2014 Feb 18.

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231-1000, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrurol.2014.21DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4339095PMC
April 2014

The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.

Eur Urol 2014 Jan 5;65(1):3-6. Epub 2013 Oct 5.

Department of Oncology, McMaster University and Escarpment Cancer Research Institute, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838130101
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2013.09.024DOI Listing
January 2014

Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib.

Oncologist 2014 Jan 5;19(1):51-60. Epub 2013 Dec 5.

Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center and the Sackler School of Medicine, Tel Aviv University, Kfar-Saba, Israel; Department of Oncology, Rambam Medical Center, Haifa, Israel; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA; Roswell Park Cancer Institute, Buffalo, New York, USA; Department of Oncology, Wolfson Medical Center, Holon, Israel; Department of Oncology, Asaf Harofe Medical Center, Zerifin, Israel; Department of Oncology, Sheba Medical Center, Tel Hashomer, Israel; Department of Oncology, Soroka University Medical Center, Beer-sheva, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2012-0335DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903056PMC
January 2014

Management of patients with biochemical recurrence after local therapy for prostate cancer.

Hematol Oncol Clin North Am 2013 Dec 18;27(6):1205-19, viii. Epub 2013 Sep 18.

Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1-1M59, Baltimore, MD 21287, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2013.08.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818691PMC
December 2013

The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer.

Urol Clin North Am 2012 Nov;39(4):573-81

Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S009401431200073
Publisher Site
http://dx.doi.org/10.1016/j.ucl.2012.07.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742094PMC
November 2012

AIM1 promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy.

Prostate 2012 Jul 29;72(10):1133-9. Epub 2011 Nov 29.

Department of Otolaryngology and Head & Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.22461DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360823PMC
July 2012

Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.

Urol Oncol 2011 Nov-Dec;29(6):670-5. Epub 2009 Dec 4.

Prostate Cancer Program, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2009.10.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483074PMC
March 2012

Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression.

Prostate 2012 Mar 17;72(4):461-7. Epub 2011 Jun 17.

The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.21447DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463372PMC
March 2012

Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials.

Cancer 2012 Mar;118(6):1533-42

Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, CRB1-1M45, 1650 Orleans Street, Baltimore, MD 21231, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.26437DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252493PMC
March 2012

Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial.

Cancer Chemother Pharmacol 2012 Mar 22;69(3):763-71. Epub 2011 Oct 22.

Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, CRB1-1M59, 1650 Orleans Street, Baltimore, MD 21231, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-011-1759-9
Publisher Site
http://dx.doi.org/10.1007/s00280-011-1759-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586214PMC
March 2012

The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.

BJU Int 2012 Jan 20;109(1):32-9. Epub 2011 Jul 20.

Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Brady Urological Institute, Johns Hopkins University, Baltimore, MD 21231, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1464-410X.2011.10422.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204323PMC
January 2012

The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.

Cancer 2011 Sep 1;117(17):3963-71. Epub 2011 Mar 1.

Texas Oncology and Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25982DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483075PMC
September 2011

A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone.

Cancer Chemother Pharmacol 2011 Feb 6;67(2):431-8. Epub 2010 May 6.

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1-1M59, Baltimore, MD 21231, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-010-1328-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028086PMC
February 2011

Novel targeted therapeutics for metastatic castration-resistant prostate cancer.

Cancer Lett 2010 May 29;291(1):1-13. Epub 2009 Aug 29.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2009.08.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029098PMC
May 2010

LHRH antagonists vs LHRH agonists: which is more beneficial in prostate cancer therapy?

Oncology (Williston Park) 2009 Jun;23(7):631-2

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
June 2009

Treat early or wait? A stubborn question that remains unanswered.

Eur Urol 2009 Jan 7;55(1):23-5; discussion 26-7. Epub 2008 Oct 7.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S030228380801191
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2008.09.067DOI Listing
January 2009

Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?

Nat Clin Pract Oncol 2009 Jan 28;6(1):12-3. Epub 2008 Oct 28.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins School of Medicine, 1650 Orleans Street, Baltimore, MD 21231,USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncponc1262DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014058PMC
January 2009

Outcomes of patients after aborted radical cystectomy for intraoperative findings of metastatic disease.

BJU Int 2008 Dec 22;102(11):1539-43. Epub 2008 Aug 22.

The Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, MD 21287-2101, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1464-410X.2008.07877.xDOI Listing
December 2008

Evolving new treatments for patients with prostate cancer: the advanced disease paradigm of the PSA era.

Urol Oncol 2008 Jul-Aug;26(4):406-7

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2007.11.001DOI Listing
September 2008

Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer?

Nat Clin Pract Urol 2008 Sep 29;5(9):480-1. Epub 2008 Jul 29.

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncpuro1175DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4036454PMC
September 2008